Molecular Pharmacology of the Interaction of Anthracyclines with Iron

X. Xu, H. L. Persson, and D. R. Richardson

Children’s Cancer Institute Australia for Medical Research, Iron Metabolism and Chelation Program, Sydney, New South Wales, Australia (X.X., D.R.R.); and Divisions of Pulmonary Medicine and Pathology II, Faculty of Health Sciences, University of Linköping, Linköping, Sweden (H.L.P.)

Received March 31, 2005; accepted May 9, 2005

ABSTRACT

Although anthracyclines such as doxorubicin are widely used antitumor agents, a major limitation for their use is the development of cardiomyopathy at high cumulative doses. This severe adverse side effect may be due to interactions with cellular iron metabolism, because iron loading promotes anthracycline-induced cell damage. On the other hand, anthracycline-induced cardiotoxicity is significantly alleviated by iron chelators (e.g., desferrioxamine and dexrazoxane). The molecular mechanisms by which anthracyclines interfere with cellular iron trafficking are complex and still unclear. Doxorubicin can directly bind iron and can perturb iron metabolism by interacting with multiple molecular targets, including the iron regulatory proteins (IRP) 1 and 2. The RNA-binding activity of these molecules regulates synthesis of the transferrin receptor 1 and ferritin, which are crucial proteins involved in iron uptake and storage, respectively. At present, it is not clear whether doxorubicin affects IRP1-RNA-binding activity by intracellular formation of doxorubicinol and/or by generation of the doxorubicin-iron(III) complex. Furthermore, doxorubicin prevents the mobilization of iron from ferritin by a mechanism that may involve lysosomal degradation of this protein. Prevention of iron mobilization from ferritin would probably disturb vital cellular functions as a result of inhibition of essential iron-dependent proteins, such as ribonucleotide reductase. This review discusses the molecular interactions of anthracyclines with iron metabolism and the development of cardioprotective strategies such as iron chelators.

Anthracyclines are potent antineoplastic agents used extensively to treat a range of cancers, including leukemias, lymphomas, sarcomas, and carcinomas (for review, see Gewirtz, 1999). Doxorubicin, daunorubicin, and epirubicin are clinically used anthracyclines (Fig. 1). The intricate and complex cellular responses to anthracyclines hinder efforts to unveil the mechanisms involved in their cytostatic and cytotoxic actions. However, anthracyclines are proposed to disrupt macromolecular biosynthesis by various mechanisms, including DNA intercalation and the inhibition of DNA polymerase and topoisomerase II (Gewirtz, 1999). Anthracyclines can also induce DNA damage by the generation of free radicals that react with a variety of macromolecules, thus inhibiting cellular proliferation or causing apoptosis (Gewirtz, 1999). In general, the antitumor effect of anthracyclines is mainly attributed to their DNA-binding and -damaging abilities. Indeed, the pharmacological aspects of these drugs have been extensively reviewed (for reviews, see Myers, 1998; Minotti et al., 2004) and will not be discussed in depth in this article.

A major problem with the clinical use of anthracyclines is their cardiotoxicity, which limits administration exceeding an accumulated dose of approximately 550 mg/m² (for re-

Received March 31, 2005; accepted May 9, 2005

ABSTRACT

Although anthracyclines such as doxorubicin are widely used antitumor agents, a major limitation for their use is the development of cardiomyopathy at high cumulative doses. This severe adverse side effect may be due to interactions with cellular iron metabolism, because iron loading promotes anthracycline-induced cell damage. On the other hand, anthracycline-induced cardiotoxicity is significantly alleviated by iron chelators (e.g., desferrioxamine and dexrazoxane). The molecular mechanisms by which anthracyclines interfere with cellular iron trafficking are complex and still unclear. Doxorubicin can directly bind iron and can perturb iron metabolism by interacting with multiple molecular targets, including the iron regulatory proteins (IRP) 1 and 2. The RNA-binding activity of these molecules regulates synthesis of the transferrin receptor 1 and ferritin, which are crucial proteins involved in iron uptake and storage, respectively. At present, it is not clear whether doxorubicin affects IRP1-RNA-binding activity by intracellular formation of doxorubicinol and/or by generation of the doxorubicin-iron(III) complex. Furthermore, doxorubicin prevents the mobilization of iron from ferritin by a mechanism that may involve lysosomal degradation of this protein. Prevention of iron mobilization from ferritin would probably disturb vital cellular functions as a result of inhibition of essential iron-dependent proteins, such as ribonucleotide reductase. This review discusses the molecular interactions of anthracyclines with iron metabolism and the development of cardioprotective strategies such as iron chelators.

Anthracyclines are potent antineoplastic agents used extensively to treat a range of cancers, including leukemias, lymphomas, sarcomas, and carcinomas (for review, see Gewirtz, 1999). Doxorubicin, daunorubicin, and epirubicin are clinically used anthracyclines (Fig. 1). The intricate and complex cellular responses to anthracyclines hinder efforts to unveil the mechanisms involved in their cytostatic and cytotoxic actions. However, anthracyclines are proposed to disrupt macromolecular biosynthesis by various mechanisms, including DNA intercalation and the inhibition of DNA polymerase and topoisomerase II (Gewirtz, 1999). Anthracyclines can also induce DNA damage by the generation of free radicals that react with a variety of macromolecules, thus inhibiting cellular proliferation or causing apoptosis (Gewirtz, 1999). In general, the antitumor effect of anthracyclines is mainly attributed to their DNA-binding and -damaging abilities. Indeed, the pharmacological aspects of these drugs have been extensively reviewed (for reviews, see Myers, 1998; Minotti et al., 2004) and will not be discussed in depth in this article.

A major problem with the clinical use of anthracyclines is their cardiotoxicity, which limits administration exceeding an accumulated dose of approximately 550 mg/m² (for re-
view, see Singal et al., 1997). The toxic effects of anthracyclines to cardiomyocytes are not the result of inhibition of DNA synthesis, because these cells do not replicate (Myers, 1998). Although the reasons for the cardiotoxicity of these drugs are not fully understood, a number of observations suggest that the interactions of anthracyclines with iron are of great importance (Minotti et al., 1998; Kotamraju et al., 2002; Kwok and Richardson, 2002, 2003). The redox state of iron can be converted between the iron(II) and iron(III) states by interaction with anthracyclines, generating toxic reactive oxygen species (ROS) (Myers, 1998; Minotti et al., 2004). Before beginning a description of the reactions of anthracyclines with iron, we will first briefly detail the molecular mechanisms involved in the processing and trafficking of intracellular iron.

**Cellular and Molecular Physiology of Iron Metabolism**

**The Transferrin–Transferrin Receptor Mechanism of Iron Uptake**

Iron is a crucial element for living cells and is found in two functional forms of macromolecules (i.e., heme and nonheme iron-containing proteins) (for review see Richardson and Ponka, 1997). In brief, ferric iron [iron(III)] is transported through the body in a soluble form bound to transferrin (molecular mass, 80 kDa), a protein mainly synthesized by the liver and also sanctuary sites such as the brain and testis. Transferrin donates iron to cells through binding to the dimeric transferrin receptor 1 (TfR1) on the cell membrane, which is subsequently endocytosed (Fig. 2). Within late endosomes at acidic pH, iron is liberated from transferrin, and in the ferrous form [iron(II)] is then transported into the cytosol by the divalent metal transporter 1 (DMT1; for review, see Napier et al., 2005). The transferrin–TfR1 complex, on the other hand, is returned to the cell surface, where apotransferrin is released from its receptor into the extracellular space (Fig. 2). The binding of transferrin to the TfR1 and the subsequent uptake of iron is regulated by a number of factors, including: 1) TfR1 expression, which is modulated by intracellular iron levels (see *The Regulation of Iron Homeostasis by Iron-Regulatory Proteins*); 2) the competitive binding of transferrin to the TfR1 by the product of the hemochromatosis (HFE) gene (Lebron et al., 1999); and 3) the saturation of transferrin with iron, because apotransferrin has a very low affinity for the TfR1 in contrast to diferric transferrin.

The description of the detailed structure of the iron-transferrin–TfR1 complex has unveiled important insights into the iron uptake process (Cheng et al., 2004). This recent investigation revealed that HFE and transferrin compete for the same binding site on each of the TfR1 monomers, which is in agreement with the findings of a previous study (Lebron et al., 1999). It is interesting that the apical part of the receptor within the transferrin–TfR1 complex remains free and potentially accessible to interaction with other molecules. It is possible that DMT1 and/or the postulated ferrooxidase, which reduces iron(III) to iron(II) within transferrin, could associate with the TfR1 at this site (Cheng et al., 2004).

A recently identified second transferrin receptor (TfR2; Kawabata et al., 1999) probably plays an important role in iron homeostasis, because mutations of this molecule can lead to hemochromatosis (Camaschella et al., 2000). Even though TfR2, like TfR1, is a type II membrane protein with a large C-terminal ectodomain and a small N-terminal cytoplasmic domain, the affinity of TfR2 for transferrin is approximately 25 times less than that of TfR1 (Kawabata et al., 1999). On the other hand, TfR1 binds to HFE with nanomolar affinity (Lebron et al., 1999), whereas HFE binding to the TfR2 is not detectable (West et al., 2000). In contrast to the iron-dependent, post-transcriptional regulation of TfR1, the expression of TfR2 is regulated, at least in part, by the erythroid transcription factor GATA-1 (Kawabata et al., 2001). It remains unclear whether there is direct interaction between TfR1 and TfR2. However, Vogt et al. (2003) have suggested that these molecules, because of their similar internalization and colocalization patterns, form heterodimers.

**Intracellular Iron Metabolism**

**Hephaestin, Ferroportin, and Hepcidin.** Apart from transferrin, TfR1, and TfR2, several other proteins have more recently been implicated in the trafficking and release of intracellular iron, including: hephaestin (Vulpe et al., 1999), ferroportin1 (Donovan et al., 2000), and hepcidin (for review, see Ganz, 2003). The hephaestin molecule is a transmembrane ceruloplasmin homolog that is markedly expressed in the intestine and was first identified in the sla mouse (Vulpe et al., 1999). The mutation in this animal leads to reduced release of iron into circulation, resulting in iron accumulation within enterocytes (Vulpe et al., 1999). Therefore, hephaestin may play a role in facilitating iron release in cooperation with the iron transporter ferroportin1, which is believed to be responsible for iron release from enterocytes into the bloodstream (Donovan et al., 2000).

Studies over the last 3 years have shown that hepcidin, a peptide hormone secreted by the liver, is critical in iron homeostasis in that it acts as a iron-regulatory hormone (Ganz, 2003). Under conditions of iron overload, hepcidin is highly expressed in the liver (Pigeon et al., 2001). It is thought that hepcidin negatively regulates intestinal iron absorption, maternal-fetal iron transport across the placenta, and iron release from hepatic stores and macrophages (Ganz, 2003). Once in the circulation, hepcidin may bind to
In cellular assays, the low-affinity form spontaneously binds mRNA and a low-affinity form unable to bind IREs (Fig. 3). In cellular assays, the low-affinity form can be converted to the high-affinity IRP-RNA binding molecule by the addition of β-mercaptoethanol. This allows an estimate of the total IRP-RNA binding activity, thus representing the total IRP present in the cell (Hentze and Kuhn, 1996).

It is noteworthy that IRP1 and IRP2 share extensive sequence homology, apart from a 73-amino acid sequence unique to IRP2 that mediates its degradation (Richardson and Ponka, 1997). The IRP2 molecule contains no [4Fe-4S] cluster, and in iron-replete cells, IRP2 is degraded by a proteasome-dependent mechanism (Guo et al., 1995). Although both IRPs are ubiquitously expressed, IRP1 is more abundant in most tissues (Kim et al., 1995). However, it should be noted that IRP2 is not a null protein. In fact, IRP2(-/-) mice develop neurodegeneration and movement-disorder symptoms because of significant iron accumulation in white matter tracts and nuclei of the brain (LaVaute et al., 2001). In contrast, IRP1(-/-) mice demonstrate normal serum chemistry, and all major tissues are without histological abnormalities (Meyron-Holtz et al., 2004). Therefore, it has been argued that IRP2 is highly expressed in many tissues and, compared with IRP1, seems to dominate the regulation of iron metabolism (Meyron-Holtz et al., 2004).

The Intraduellar Labile Iron Pool. After iron(II) is transported out of the endosome, it enters the intracellular iron pool or labile iron pool (Fig. 2). This entity is not well understood, although it is usually thought to be composed of chelatable iron [iron(II) and iron(III)], associated with low-M₆ ligands, such as citrate or ATP (Richardson and Ponka, 1997). More recent work has failed to demonstrate the presence of low-M₆ intermediates in the iron uptake process, and the possible involvement of high-M₆ iron-binding chaperone molecules has been suggested (Petrak and Vyoral, 2001). On the other hand, or in combination with iron-binding chaperone proteins, interactions between organelles such as the mitochondria and the endosomal membrane by DMT1. Upon leaving the endosome, the iron becomes part of a poorly characterized compartment known as the intracellular labile iron pool. Iron can be redistributed from the labile iron pool for cellular use, stored in ferritin, or potentially pumped out of the cell by ferroportin1. Doxorubicin and other anthracyclines bind iron to form drug-iron(III) complex, which is known to generate ROS and to lead to cellular damage and apoptosis.
endosome and mitochondrion might be involved in intracellular iron trafficking (Richardson and Ponka, 1997; Zhang et al., 2005). Irrespective of its character, the labile iron pool donates iron to a variety of iron-containing molecules required for cellular metabolism and also for iron storage in ferritin.

The labile iron pool is generally referred to as being cytosolic and represents <5% of total cellular iron (for review, see Esposito et al., 2002). A transit pool of chelatable iron is also required in the mitochondrion during heme synthesis, and chelatable redox-active iron may exist within other organelles (for review, see Napier et al., 2005). However, the size and molecular nature of these different subcellular iron pools remains to be investigated. A growing body of evidence suggests that a significant amount of iron, mainly in a redox-active form, is located within the lysosome (Persson et al., 2001). The concentration and distribution of chelatable iron in different intracellular compartments in rat hepatocytes has been determined via quantitative laser scanning microscopy using the fluorescent chelator Phen Green (Petrat et al., 2001). The highest concentration of iron (15.8 ± 4.1 μM) was in a subgroup of endosomes and/or lysosomes that may be responsible for degrading iron-containing proteins and mitochondria (Petrat et al., 2001). In comparison, all other cellular compartments demonstrated significantly lower concentrations of chelatable iron; for instance, the mitochondria and nucleus had 3-fold lower iron levels.

Iron Storage in Ferritin and Lysosomal Iron Recycling. Iron that is not immediately required for cell function or synthesis of hemoproteins is deposited in the iron-storage protein ferritin (Fig. 2). Ferritin is composed of 24 subunits categorized into two subtypes: a heavy subunit (M, 21) and a light subunit (L-Ft; Mr 19) that polymerize into a high-Mr polymer (Mr 430–450) (for review, see Harrison and Arosio, 1996). The heavy and light ferritin subunits display approximately 55% amino acid sequence identity and have a similar three-dimensional structure. The ferritin molecule is able to accommodate approximately 4500 iron atoms in its protein shell. Ferritin stores iron(II) by forming a solid oxo-mineral in its core (Harrison and Arosio, 1996). It is suggested that the ferritin H-subunit subunits induce a rapid oxidation of iron(II) to iron(III) through a ferroxidase site composed of seven conserved residues. The L-ferritin subunit on the other hand, has a nucleation site that is involved in the formation of the iron core (Harrison and Arosio, 1996).

Present knowledge favors the notion of the lysosomal pathway as a significant route for ferritin degradation and reutilization of iron (Radisky and Kaplan, 1998; Persson et al., 2001). Lysosomes degrade various macromolecules, including metalloproteins such as ferritin, and damaged cell organelles. Because of lysosomal autophagy, lysosomes become particularly rich in iron (Persson et al., 2001; Petrat et al., 2001). Solubilized lysosomal iron is either transported to the cytosol by an unknown mechanism or is stored within lysosomes as iron(III) in hemosiderin (i.e., partially degraded ferritin) (Persson et al., 2001).

Iron-Related Mechanisms for Anthracycline-Induced Cardiotoxicity

The cardiotoxic effects of anthracyclines have been suggested to be a result of a number of different mechanisms. These are discussed below with emphasis on the role of iron.

Cardiotoxicity Mediated by Iron-Anthracycline Complexes and Free Radical Generation

Anthracyclines bind avidly to iron, forming a 1:1, 2:1, or 3:1 drug-to-metal complex (Fig. 1), with an overall association constant of 10¹⁸ (Gianni and Myers, 1992). Doxorubicin can directly bind iron and, in the presence of oxygen, it can cycle between the iron(II) and iron(III) states (Fig. 4). The doxorubicin-iron(III) complex can be reduced to the doxorubicin-iron(II) complex in the presence of reducing agents such as NADPH cytochrome P450 reductase, glutathione, and cysteine. These reactions are accompanied by the formation of O₂⁻ and the conversion of anthracycline quinone moieties to semiquinone free radicals (Fig. 4). The quinone structure of......
Anthracyclines has the potential to act as an electron acceptor from enzymes such as flavin reductases, NADH dehydrogenase, and cytochrome P450 reductase (Gianni and Myers, 1992). Through the iron-catalyzed Haber-Weiss reaction, \( \text{H}_2\text{O}_2 \) and extremely reactive hydroxyl radicals are generated. The semiquinone radical may transform to an aglycone C7-centered radical, which is a potent alkylating agent (Fig. 4) (Jung and Reszka, 2001). It is well known that such ROS generation by anthracyclines causes DNA damage and apoptosis (Minotti et al., 2004).

Although neither \( \text{H}_2\text{O}_2 \) nor \( \text{O}_2^- \) is particularly reactive, in the presence of redox-active iron, even low quantities of ROS are cytotoxic. Because all cells contain small amounts of redox-active iron, formation of hydroxyl radicals [or similarly reactive iron-centered (ferryl and perferryl) radicals] can be promoted under appropriate conditions. These highly reactive species can attack almost all cellular constituents and a number of organelles and create chain reactions that lead to cell death (Myers, 1998). The increased activity of the antioxidant pathways, such as catalase, glutathione peroxidase, and glutathione transferase, in anthracycline-exposed cardiomyocytes further supports the great importance of ROS formation in cardiac injury secondary to anthracycline treatment (Jung and Reszka, 2001). However, cardiac tissue is generally recognized to be quite vulnerable to free radical damage caused by the low activity of antioxidant enzyme systems (Gianni and Meyers, 1992). Finally, it should also be noted that there is evidence that the cytotoxic mechanisms of anthracyclines can be independent of ROS generation (Keizer et al., 1990; Wu and Hasnoff, 2005).

**Anthracyclines Mediate Dysregulation of Iron Homeostasis**

A number of studies have provided evidence for mechanisms that could be involved in anthracycline-mediated cardiotoxicity that are both independent and dependent on iron. Below, we focus upon the iron-dependent mechanisms of anthracycline-mediated cardiotoxicity.

**Effect of Doxorubicin on Major Regulators of Iron Homeostasis: IRP1 and IRP2.**

The role of doxorubicin in decreasing IRP-RNA binding activity. The effect of doxorubicin on cellular iron homeostasis, including IRP levels, has been suggested to be a factor contributing to its cardiotoxicity (Minotti et al., 1995, 1998). The mechanisms involved in the effect of doxorubicin on IRP1 remain controversial; a number of research groups have shown different results. At first, doxorubicinol, a secondary alcohol metabolite of doxorubicin, was described to interact with the [4Fe-4S] cluster of IRP1, resulting in the release of iron(II) and a decrease in cytoplasmic aconitase activity (Minotti et al., 1995, 1998; Brazzolotto et al., 2003). Considering classic IRP theory, decreased cytoplasmic aconitase levels may result in increased IRP-RNA binding (Hentze and Kuhn, 1996). In contrast, doxorubicinol led to a decrease in IRP-RNA binding that could not be reversed by the reducing agent, \( \beta \)-mercaptoethanol (Minotti et al., 1998). It was suggested that doxorubicinol in the presence of the aconitase substrate cis-aconitate directly removed iron(II) from the [Fe-S] cluster from IRP1 by a mechanism independent of free radical generation (Minotti et al., 1998) (Fig. 5, Fig. 4. Illustration of doxorubicin-mediated redox cycling. Doxorubicin can bind to iron by forming doxorubicin-iron(III) complexes, which may lead to ROS formation and cellular damage. One electron reduction of doxorubicin generates the doxorubicin-semiquinone that induces DNA damage and lipid peroxidation by ROS formation. The semiquinone radical can be transformed to a C7 radical that can also mediate cellular damage. The reduction of doxorubicin by two electrons generates a secondary alcohol metabolite, doxorubicinol. Although it is clear that doxorubicin affects cellular IRP1 RNA binding activity and iron homeostasis, it is debatable whether doxorubicinol, the doxorubicin-iron(III) complex, or both are active molecular effectors.
Moreover, a generalized model was proposed indicating that the interaction of doxorubicinol with IRP1 resulted in iron(II) release from the [4Fe-4S] cluster and the reoxidation of doxorubicin to doxorubicin. The iron(II) released then formed a complex with doxorubicin that irreversibly inactivated IRP1 (Minotti et al., 1998).

In the investigation by Minotti et al. (1998) described above, lysates from homogenized hearts incubated with iron salts and cysteine were implemented to reconstitute the [4Fe-4S] cluster of IRP-1. Clearly, this system is undefined and the exact molecular site of the iron mobilization observed in the lysates was not identified. Indeed, it was not clear whether the iron release in the lysates after incubation with anthracyclines was due to mobilization of iron from IRP1 or other molecules (Minotti et al., 1998). Later studies by the same authors showed that incubation of a cardiomyocyte cell line with doxorubicin increased active IRP-RNA binding but decreased aconitase activity (Fig. 5, Scheme 2) (Minotti et al., 2001). These authors suggested that the sequential action of doxorubicinol and ROS on IRP1 leads to the generation of the null protein. However, it was not clear from this latter article why an increase in IRP1-RNA-binding was observed, in contrast to the decrease previously observed in heart lysates (Minotti et al., 1998).

Further studies by other investigators assessed the effect of doxorubicin in GLC4 small-cell lung carcinoma cells resistant and sensitive to this agent (Brazzolotto et al., 2003). These authors showed that incubating doxorubicin with the sensitive cell type resulted in a decrease in IRP-IRE-binding activity, whereas it had no effect on the resistant clone (Brazzolotto et al., 2003). When recombinant human IRP1 was incubated with high concentrations of doxorubicin or doxorubicinol (120 μM), aconitase activity was significantly reduced only after doxorubicinol treatment in the presence of oxygen. These concentrations of anthracyclines are well above those encountered within human patients administered doxorubicin, where serum concentrations reach micromolar levels. In contrast, doxorubicin had no effect on purified recombinant IRP2, suggesting that doxorubicin targeted IRP1 (Brazzolotto et al., 2003). This latter result was not consistent with previous studies showing that incubation of doxorubicin cell lines or primary cultures with doxorubicin reduced IRP2-RNA-binding activity (Minotti et al., 2001; Kwok and Richardson, 2002).

The role of the doxorubicin-iron complex in decreasing IRP-RNA binding activity. In subsequent studies by others, three anthracyclines, namely doxorubicin, daunorubicin, and epirubicin, had a complex effect on IRP-RNA binding activity when incubated with cells in culture (Kwok and Richardson, 2002). In these experiments, active IRP-RNA binding activity decreased over a 6-h incubation with anthracyclines and then subsequently increased, whereas total IRP-RNA binding decreased as a function of time. In contrast to a previous investigation by Minotti and coworkers (1998), experiments using cell lysates demonstrated that doxorubicinol in the presence or absence of cis-aconitate had no effect on IRP-RNA binding (Kwok and Richardson, 2002). In contrast, anthracycline-Fe and -Cu complexes reduced active IRP-RNA binding, which was reversible upon the addition of β-mercaptoethanol (Kwok and Richardson, 2002). These latter results differed from those of Minotti and associates (1998) using tissue homogenates, which suggested that the doxorubicin-iron complex irreversibly inactivated IRP-RNA binding. This inhibitory effect could be due to the ability of the doxorubicin-iron complex to oxidize critical sulphydryl groups involved in IRP-mRNA binding activity (Philpott et al., 1993) (Fig. 5, Scheme 3). In this way, the doxorubicin-iron complex would act similarly to other agents that react with sulphydryl groups, such as diamide (Philpott et al., 1993). Considering this, it is well known that the doxorubicin-iron complex catalyzes a range of redox reactions. For instance, it reacts with reductants, including glutathione, to yield oxidized thiols and oxygen radicals (Gianni and Myers, 1992).

Using primary cultures of cardiomyocytes, Kwok and Richardson (2002) also reported that doxorubicin reduced IRP2-RNA-binding activity. These studies are similar to those reported using the H9c2 cardiomyocyte cell line, where doxorubicin irreversibly decreased IRP2-RNA-binding activity (Minotti et al., 2001). Because IRP2 does not possess an [Fe-S] cluster, it can be speculated that the effects of doxorubicin may also be mediated by its ability to oxidize sulphydryl groups involved in mRNA binding activity. Indeed,
anthracycline-mediated free radical production may be involved in this process because 5-iminodaunorubicin, which generates far lower levels of free radicals, does not affect IRP2-RNA binding activity (Minotti et al., 2001).

**Doxorubicin increases IRP-RNA binding activity in endothelial cells.** Studies using endothelial cells have shown different effects of doxorubicin on IRP-RNA binding activity than those described above. In fact, in an investigation by Kotamraju and colleagues (2002), doxorubicin increased IRP-RNA binding activity within 8 h, and there was also increased iron uptake and TfR1 expression. These experiments suggested that doxorubicin-induced iron uptake occurred via increased IRP-RNA binding activity and the subsequent elevation of TfR1 levels (Kotamraju et al., 2002). These authors proposed that oxidative stress generated by doxorubicin activated IRP-RNA binding, as antioxidants, such as ebselen and Mn(III) tetrakis(4-benzoic acid)porphyrin complex, inhibited the effect of doxorubicin on TfR1 levels and iron uptake. These results were clearly different from those using lysates from the homogenized heart (Minotti et al., 1998) or neoplastic cell lines, where doxorubicin decreased IRP-RNA binding and may indicate a cell type-specific response.

In conclusion, the results above demonstrate that the effects of doxorubicin on IRP-RNA binding activity are complex. In general, in most cell types, doxorubicin decreased active IRP-RNA binding activity, and this will probably result in important downstream effects on cellular iron metabolism. Further studies to clarify the precise molecular mechanisms involved need to be performed.

**Effect of Doxorubicin on Iron Trafficking Pathways: Doxorubicin Induces Iron Accumulation in Ferritin.** Initial studies assessing the effects of doxorubicin on cellular iron metabolism reported that doxorubicin released iron from ferritin (Thomas and Aust, 1986). However, these experiments were performed in vitro using the purified ferritin protein and their physiological significance remained unclear. More recent investigations showed that a 24-h incubation of a range of neoplastic and normal cells with diferric transferrin and doxorubicin (1–10 μM) led to ferritin-iron levels 3- to 8-fold higher than those of control cells incubated with diferric transferrin alone (Kwok and Richardson, 2003, 2004). This accumulation of ferritin-iron occurred because incubation of cells with anthracyclines prevented iron release from this molecule (Fig. 6). Moreover, the slight increase in ferritin protein levels observed after incubation with doxorubicin (to 130% of the control at 5 μM doxorubicin) could not account for the 3- to 8-fold increase in ferritin-iron accumulation (Kwok and Richardson, 2003).

Considering the mechanism of ferritin-iron accumulation after incubation with doxorubicin, the general process of iron mobilization from this protein is poorly understood. However, catabolism of ferritin by lysosomes has been suggested to be a likely mechanism (Radisky and Kaplan, 1998; Persson et al., 2001). In addition, anthracyclines are known to accumulate in lysosomes (Hurwitz et al., 1997), and this organelle may be a target for these drugs (Fig. 6). Recent studies have shown that ferritin iron mobilization is an energy-dependent process that also requires protein synthesis (Kwok and Richardson, 2004). This latter observation was based on studies inhibiting protein synthesis using cycloheximide, which prevented ferritin iron release (Kwok and Richardson, 2004). It can be speculated that this effect could be a result of the requirement for translation of a protein that is involved in ferritin iron mobilization. Additional evidence for the involvement of the lysosome in the doxorubicin-mediated inhibition of ferritin iron mobilization was provided by implementing a number of lysosomal protease inhibitors (Kwok and Richardson, 2004). Depression of lysosomal protease activity using pepstatin A, E64d, or leupeptin demonstrated that peptatin A had no effect, whereas E64d and leupeptin increased ferritin iron-loading to a level similar to that of doxorubicin. Considering this, because pepstatin A is an aspartic protease inhibitor, whereas E64d and leupeptin are cysteine or cysteine and serine protease inhibitors, respectively, it can be suggested that aspartic proteases are not involved in ferritin-iron mobilization (Kwok and Richardson, 2004). Further support for the role of the lysosome and/or proteasome in ferritin-iron mobilization was achieved through the use of the lysomotropic agents NH₄Cl, chloroquine, and methylamine and the

![Fig. 6. Schematic illustration of the effect of doxorubicin on cellular iron metabolism. Doxorubicin leads to iron accumulation in ferritin as a result of inhibition of iron mobilization from this protein. There is no change in the total amount of iron in the cell; rather, only the intracellular distribution is markedly affected. The mechanism by which doxorubicin inhibits iron release from ferritin is not known, but may involve, at least in part, disturbance to lysosomal function. Indeed, the lysosome has been reported to be involved in ferritin degradation, and the release of iron from this protein. The inability of ferritin to release iron after exposure to doxorubicin may lead to cytotoxic effects because of the requirement of essential metabolic processes for iron (e.g., DNA synthesis). Clearly, this potential growth-inhibitory mechanism is not the only one mediated by anthracyclines.](image-url)
and iron metabolism are involved in the cytotoxic effects of doxorubicin treatment. Ferritin-iron mobilization is a target for anthracycline-mediated cardiotoxicity (Kwok and Richardson, 2004). Concomitant experiments showed that preincubation with ferric ammonium citrate, whereas incubation with 5-iminodaunorubicin reportedly produces less ROS than 5-iminodaunorubicin did not protect the cell. Considering that the inhibition of ferritin iron mobilization contributes to cardiotoxicity, it must be noted that this is only one of the many effects of these drugs that contributes to their cytotoxicity. At present, compared with the other cytotoxic effector mechanism of anthracyclines, the extent to which the inhibition of ferritin iron mobilization contributes to cardiotoxicity is not clear. Furthermore, it must be noted that the potential cytotoxicity induced by inhibiting ferritin iron mobilization is at odds with the ability of iron chelators to prevent anthracycline-mediated cardiotoxicity (see Agents that Prevent Doxorubicin-Mediated Cardiotoxicity by Interacting with Iron). In terms of trying to understand this apparent dichotomy, the complexity of the mechanisms of action of anthracyclines must be considered (Minotti et al., 2004). In fact, the iron pool or other molecular sites that are targeted by chelators to prevent anthracycline-mediated cardiotoxicity are not known, and it is interesting that the chelator, dexrazoxane, does not completely prevent this problem (Swain et al., 1997b). Additional studies investigating the mechanisms by which chelators inhibit anthracycline-mediated cardiotoxicity are required.

It is interesting that, similar to anthracyclines, a number of free radical-generating agents (i.e., menadione and paraquat) have also been shown to be effective at increasing ferritin iron accumulation, an effect that can be at least partially reversed by free radical scavengers (Kwok and Richardson, 2003). It has been proposed that the ability of free radical generators to induce ferritin iron accumulation might be mediated via the effects of these agents on lysosomal function (Kwok and Richardson, 2004). Further evidence for a role of free radical generation in inducing the alterations in ferritin-iron metabolism was obtained by Corna et al. (2004), comparing doxorubicin and the redox-active anthracycline analogs mitoxantrone and 5-iminodaunorubicin. These ROS-generating compounds were found to significantly induce ferritin protein expression, especially the H-ferritin subunit, suggesting that doxorubicin regulates ferritin levels via ROS formation (Corna et al., 2004). Further experiments revealed that the ROS scavenger N-acetylcysteine could prevent enhanced ROS production and ferritin accumulation after doxorubicin treatment. Therefore, it was suggested that doxorubicin-mediated ROS production was involved in ferritin induction in the H9c2 cardiomyocyte cell line (Corna et al., 2004). Concomitant experiments showed that preincubation of doxorubicin or mitoxantrone could paradoxically protect H9c2 cells from cytotoxicity induced by iron loading with ferric ammonium citrate, whereas incubation with 5-iminodaunorubicin did not protect the cell. Considering that 5-iminodaunorubicin reportedly produces less ROS than either doxorubicin or mitoxantrone, these studies suggested that the protective effect of these compounds on iron-loading seemed to correlate with their ability to act as ROS generators (Corna et al., 2004). Apart from the effect of doxorubicin on ferritin iron-loading, further evidence that interactions between doxorubicin and iron metabolism are involved in the cytotoxic effects of these drugs has been provided by studies examining HFE knockout mice (Miranda et al., 2003). After doxorubicin treatment, HFE knockout mice accumulate more iron in the serum and several organs compared with their wild-type counterparts, suggesting that HFE deficiency may increase susceptibility to doxorubicin-induced toxicity (Miranda et al., 2003). HFE-deficient mice treated with doxorubicin also have higher mortality rates and a greater degree of mitochondrial damage compared with the control (Miranda et al., 2003).

**Agents that Prevent Doxorubicin-Mediated Cardiotoxicity by Interacting with Iron**

The evidence presented above indicates that anthracyclines markedly disturb intracellular iron metabolism; a variety of studies has clearly shown that iron plays an important role in the cardiotoxicity mediated by this drug. Apart from this, it is well known that the iron chelator, dexrazoxane (also known as ICRF-187), is an effective cardioprotective agent against the effects of doxorubicin. Below, we discuss the potential of iron chelators as agents to prevent anthracycline-mediated cardiotoxicity.

**Dexrazoxane**

The only clinically approved chelator that is currently used to alleviate doxorubicin-induced cardiotoxicity is dexrazoxane (Swain et al., 1997a,b; Minotti et al., 2004) (Fig. 7). It is suggested that in vivo, dexrazoxane permeates the cell membrane and can be rapidly hydrolyzed to its metal ion-binding metabolite, ADR-925, thus decreasing anthracycline-iron binding and ROS formation (Hasinoff, 1998). ADR-925 quickly displaces iron(III) and copper(II) from their complexes with anthracyclines, indicating that ADR-925 chelates iron(III) more strongly than doxorubicin (Hasinoff, 1998). It is interesting that metal ions, including the anthracycline-iron(III) complex, promote formation of ADR-925 and potentiate its metal chelating effect (Hasinoff, 1998).

Dexrazoxane has shown significant protection against cardiotoxicity caused by doxorubicin in numerous animal models (e.g., mouse, rat, hamster, rabbit, and dog) (Minotti et al., 2004). In addition, clinical trials showed that dexrazoxane protects patients with advanced breast cancer from doxorubicin-induced cardiotoxicity (Swain et al., 1997b).
mulated dosage of doxorubicin is not recommended only for adult patients who have received an accumulated dosage of doxorubicin ≥300 mg/m² (Gewirtz, 1999). However, this agent does not confer absolute cardioprotection (Swain et al., 1997b) and does cause myelosuppression (Curran et al., 1991). Considering this, other regimens of chelation therapy using a variety of ligands have been investigated, and these are discussed below.

**Desferrioxamine**

Desferrioxamine (Fig. 7) is a hexadentate iron chelator widely used for iron overload disease, such as β-thalassemia major (for review, see Richardson and Pronka, 1998). Desferrioxamine significantly reduces iron storage and ferritin levels and has been used for many years to control the iron loading observed in transfusion-dependent anemias (Richardson and Pronka, 1998). However, in comparison, there have been relatively few investigations assessing its protective effects against anthracycline-mediated cardiotoxicity. An early study found that after incubating isolated mice atria with doxorubicin (30 μM), desferrioxamine (200 μM) was more effective than dexrazoxane (200 μM) at preventing the doxorubicin-induced decrease in contractile force (Voest et al., 1994). In addition, Saad et al. (2001) found that desferrioxamine was highly effective at protecting against short-term doxorubicin-induced cardiotoxicity when used at a dose that was 10-fold greater than doxorubicin. Treatment with desferrioxamine either before or after doxorubicin administration reduced the doxorubicin-mediated elevation of such cardiac isoenzymes as creatine kinase isoenzyme and lactate dehydrogenase, which are indicators of myocardial damage and compromised cellular integrity, respectively (Saad et al., 2001). However, desferrioxamine is limited to subcutaneous or intravenous infusion because of its poor absorption from the gastrointestinal tract and its short plasma half-life (Aouad et al., 2002). Moreover, considering that chelator permeability is critical to the ability of these compounds to inhibit anthracycline-mediated cardiotoxicity (Voest et al., 1994), the limited membrane permeability of desferrioxamine probably explains the need for high levels of this chelator to inhibit the effects of doxorubicin (Saad et al., 2001). These disadvantages have encouraged the design of orally active chelators with high lipophilicity and membrane permeability that can access intracellular iron pools to inhibit anthracycline-mediated cardiotoxicity.

**Other Iron Chelators with Potential Cardioprotective Activity**

Pyridoxal isonicotinoyl hydrazone (PIH) (Fig. 7) is a relatively lipophilic, orally effective, tridentate iron chelator that has high membrane permeability and possesses marked iron chelation efficacy (for review, see Richardson and Pronka, 1998). In fact, PIH is able to remove iron from a variety of rodent models via the biliary route (Richardson and Pronka, 1998; Link et al., 2003). Moreover, low doses of PIH (30 mg/kg/day) given to iron-loaded human patients increased iron excretion (Richardson and Pronka, 1998). In a recent in vivo study, PIH pretreatment protected rabbits from daunorubicin-mediated toxicity, although its efficacy was not as great as dexrazoxane (Simunek et al., 2005). This study showed that repeated administration of daunorubicin to rabbits (3 mg/kg, i.v., once a week for 10 weeks) led to 4 deaths, whereas all animals survived when PIH was administered 60 min before daunorubicin. Salicylaldehyde isonicotinoyl hydrazone (SIH; Fig. 7), a PIH analog, also showed cardioprotective potential by restoring a loss in cytochrome P450 activity after daunorubicin treatment (Schroterova et al., 2004). Hence, this class of chelators shows promise as potential cardioprotective agents and requires further investigation.

Other chelators with possible potential in the treatment of anthracycline-mediated cardiotoxicity include the new orally active chelator, ICL670A (Fig. 7). This compound belongs to the synthetic tridentate and iron-selective ligands of the bis-hydroxyphenyl-triazole class (Nisbet-Brown et al., 2003). Using the hypertransfused rat model, ICL670A was able to remove iron from parenchymal iron stores four to five times more effectively than desferrioxamine (Hershko et al., 2001). In addition, the combination of desferrioxamine and ICL670A demonstrated an additive effect at the lower dose range of 25 to 50 mg/kg (Hershko et al., 2001). Phase I and II clinical trials of ICL670A were successful in patients with transfusional iron overload (Nisbet-Brown et al., 2003). However, a recent study on neonatal rat cardiac myocytes showed that ICL670A was unable to protect these cells from doxorubicin-mediated cardiotoxicity as measured by lactate dehydrogenase release, whereas dexrazoxane significantly prevented this (Hasinoff et al., 2003). The inability of ICL-670A to prevent anthracycline-mediated cardiotoxicity is puzzling, but it could be related to its inability to access appropriate pools of iron that could be the potential targets of anthracyclines. Understanding why some chelators are protective against anthracycline-mediated cardiotoxicity and others are not is important for the rational design of new cardioprotective agents and understanding the mechanism of action of these drugs.

**Summary**

Anthracyclines avidly bind iron and form anthracycline-iron(III) complexes that may serve as regulators of cellular iron homeostasis by generally decreasing IRP-RNA binding activity. However, the precise molecular mechanism of this effect remains controversial with the doxorubicin-iron complex and/or doxorubicinol being involved. Another molecular target of doxorubicin includes the iron-storage protein ferritin. Recent experiments suggest that anthracyclines prevent ferritin iron mobilization through a mechanism that may involve inhibition of the lysosomal function involved in ferritin degradation. The prevention of iron release from ferritin may be detrimental to the cell because of the importance of iron for DNA synthesis and energy metabolism. On the other hand, it has been suggested that doxorubicin-mediated ferritin iron accumulation is a protective effect against anthracycline-induced free radical generation.

Because of the role of iron in anthracycline-mediated cardiotoxicity, both dexrazoxane and other chelators such as desferrioxamine have proven to be successful cardioprotective...
tive agents. Because these two chelators have limitations, including myelotoxicity and a cumbersome administration regimen, respectively, other chelators that are orally effective are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to alleviate are being developed. Indeed, the ligands PIH, SIH, and ICL670A are under investigation, and their ability to allev...


Address correspondence to: Dr. D. R. Richardson, Children's Cancer Institute Australia for Medical Research, Iron Metabolism and Chelation Program, PO Box 81, High St, Randwick, Sydney, New South Wales, 2031 Australia. E-mail: d.richardson@ccia.org.au